Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Vigabatrin.

J A French1

  • 1Department of Neurology, University of Pennsylvania, Philadelphia 19104, USA.

Epilepsia
|October 26, 1999
PubMed
Summary
This summary is machine-generated.

Vigabatrin (VGB), an antiepileptic drug, increases central nervous system (CNS) gamma-amino butyric acid (GABA) levels by inhibiting GABA-transaminase. This review covers VGB's mechanism, pharmacokinetics, safety, and efficacy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sex differences in vocal structure in a callitrichid primate, Leontopithecus rosalia.

American journal of primatology·2020
Same author

Evidence-Based Guideline: Management of an Unprovoked First Seizure in Adults: Report of the Guideline Development Subcommittee of the American Academy of Neurology and the American Epilepsy Society.

Epilepsy currents·2015
Same author

Efficacy and safety of extended-release oxcarbazepine (Oxtellar XR™) as adjunctive therapy in patients with refractory partial-onset seizures: a randomized controlled trial.

Acta neurologica Scandinavica·2013
Same author

Evidence-based guideline: Antiepileptic drug selection for people with HIV/AIDS: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Ad Hoc Task Force of the Commission on Therapeutic Strategies of the International League Against Epilepsy.

Neurology·2012
Same author

Minimal mortality benefit with early surgery for high-risk fractured hip patients.

British journal of anaesthesia·2011
Same author

Randomized, double-blind, placebo-controlled trial of ezogabine (retigabine) in partial epilepsy.

Neurology·2011
Same journal

Responsible use of artificial intelligence in peer-reviewed publications in epilepsy.

Epilepsia·2026
Same journal

Altered autonomic balance drives the increase in cardiac output and arterial pressure during convulsive seizures in nonanesthetized sheep.

Epilepsia·2026
Same journal

Diagnostic yield and copy number variants findings in 219 adult patients with developmental and epileptic encephalopathy.

Epilepsia·2026
Same journal

Prolonged fenfluramine use in open-label studies of Dravet or Lennox-Gastaut syndromes: Long-term safety, tolerability, patient global functioning, and considerations for interpreting effectiveness.

Epilepsia·2026
Same journal

Electrocardiography characteristics and long-term mortality in people with epilepsy from a resource-poor community.

Epilepsia·2026
Same journal

Factors associated with rapid pediatric acute seizure emergency treatment: Quality Improvement in Time to Treat Status Epilepticus baseline cohort.

Epilepsia·2026
See all related articles

Area of Science:

  • Neuroscience
  • Pharmacology

Background:

  • Vigabatrin (VGB) is a structural analogue of gamma-amino butyric acid (GABA).
  • VGB functions by irreversibly inhibiting GABA-transaminase, increasing CNS GABA levels.
  • VGB is a targeted mechanism antiepileptic drug (AED), similar to Tiagabine.

Purpose of the Study:

  • To review the mechanism of action of Vigabatrin (VGB).
  • To discuss the pharmacokinetics of VGB.
  • To examine the safety and efficacy of VGB, considering recent concerns.

Main Methods:

  • Literature review of existing studies on Vigabatrin (VGB).
  • Analysis of pharmacokinetic data.
  • Evaluation of clinical trial data regarding safety and efficacy.

Related Experiment Videos

Main Results:

  • VGB's mechanism of action as a GABA-transaminase inhibitor is well-understood.
  • Pharmacokinetic profile of VGB discussed.
  • Recent safety concerns associated with VGB use highlighted.

Conclusions:

  • Vigabatrin (VGB) is an effective AED with a clear mechanism of action.
  • Understanding VGB's pharmacokinetics is crucial for its application.
  • Ongoing evaluation of VGB safety is necessary.